One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Abraham Michael Lincoff, Kirstine Brown‐Frandsen, Helen Martina Colhoun, John Eric Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner and 6 more
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Lincoff, A. M., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J. E., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/nejmoa2307563
Lincoff, Abraham Michael, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine, vol. 389, no. 24, 2023, pp. 2221–2232, https://doi.org/10.1056/nejmoa2307563.
Lincoff, Abraham Michael, Kirstine Brown‐Frandsen, Helen Martina Colhoun, John Eric Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine 389, no. 24 (2023): 2221–2232. https://doi.org/10.1056/nejmoa2307563.
Lincoff A. M., Brown‐Frandsen K., Colhoun H. M. [и др.] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes // New England Journal of Medicine. — 2023. — Vol. 389, № 24. — P. 2221–2232. — URL: https://doi.org/10.1056/nejmoa2307563
@article{lincoff2023semaglutide,
title = {{Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes}},
author = {Abraham Michael Lincoff and Kirstine Brown‐Frandsen and Helen Martina Colhoun and John Eric Deanfield and Scott S. Emerson and Sille Esbjerg and Søren Hardt‐Lindberg and G. Kees Hovingh and Steven E. Kahn and Robert F. Kushner and Ildiko Lingvay and Tuğçe Kalaycı Oral and Marie Mide Michelsen and Jorge Plutzky and Christoffer Wenzel Tornøe and Donna H. Ryan},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {24},
pages = {2221--2232},
doi = {10.1056/nejmoa2307563},
url = {https://doi.org/10.1056/nejmoa2307563}
}TY - JOUR AU - Lincoff, Abraham Michael AU - Brown‐Frandsen, Kirstine AU - Colhoun, Helen Martina AU - Deanfield, John Eric AU - Emerson, Scott S. AU - Esbjerg, Sille AU - Hardt‐Lindberg, Søren AU - Hovingh, G. Kees AU - Kahn, Steven E. AU - Kushner, Robert F. AU - Lingvay, Ildiko AU - Oral, Tuğçe Kalaycı AU - Michelsen, Marie Mide AU - Plutzky, Jorge AU - Tornøe, Christoffer Wenzel AU - Ryan, Donna H. TI - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes JO - New England Journal of Medicine VL - 389 IS - 24 SP - 2221 EP - 2232 PY - 2023 DA - 2023/11/11 DO - 10.1056/nejmoa2307563 UR - https://doi.org/10.1056/nejmoa2307563 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.